Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

BMRN Relative to the S&P 500

BMRN Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the BioMarin Pharmaceutical, Inc. (NASD:BMRN) seasonal charts above shows that a Buy Date of October 25 and a Sell Date of January 19 has resulted in a geometric average return of 12.25% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 17 of those periods. This is a very good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 10.25% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

BioMarin’s focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin’s Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.

To download BMRN seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: BMRN